darbepoetin alfa Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
erythropoietin type blood factors 5157 209810-58-2

Description:

MoleculeDescription

Synonyms:

  • darbepoetin alfa
  • aranesp
acts exactly like the natural erythropoietin made by the body to stimulate red blood cell production, but it is very slightly different in its structure
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4.50 mcg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 17, 2001 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 10098.22 12.86 5053 34319 330495 46316195
Hospitalisation 4484.43 12.86 1761 37611 61624 46585066
Investigation 1115.14 12.86 262 39110 1372 46645318
Haemodialysis 972.77 12.86 345 39027 8872 46637818
Aplasia pure red cell 894.94 12.86 271 39101 4154 46642536
Transplant 483.32 12.86 112 39260 545 46646145
Arteriovenous fistula site complication 462.45 12.86 103 39269 404 46646286
Dialysis 356.53 12.86 173 39199 9943 46636747
Haemoglobin decreased 257.50 12.86 420 38952 128529 46518161
Anaemia 241.82 12.86 610 38762 255169 46391521
Terminal state 228.66 12.86 82 39290 2172 46644518
Peritoneal dialysis 210.09 12.86 51 39321 313 46646377
Renal transplant 185.07 12.86 61 39311 1244 46645446
Renal disorder 180.52 12.86 162 39210 26524 46620166
Drug ineffective 176.47 12.86 188 39184 677650 45969040
Rheumatoid arthritis 172.51 12.86 7 39365 240208 46406482
Haemoglobin abnormal 160.91 12.86 77 39295 4286 46642404
Therapeutic response decreased 150.88 12.86 184 39188 42961 46603729
Palliative care 147.97 12.86 37 39335 261 46646429
Shunt occlusion 131.73 12.86 37 39335 427 46646263
Shunt stenosis 123.36 12.86 32 39340 266 46646424
Drug hypersensitivity 109.02 12.86 35 39337 243790 46402900
Anti-erythropoietin antibody positive 107.63 12.86 31 39341 394 46646296
Headache 100.94 12.86 155 39217 478197 46168493
Arteriovenous fistula operation 88.56 12.86 24 39348 240 46646450
Toxicity to various agents 88.46 12.86 34 39338 211732 46434958
Transfusion 86.84 12.86 79 39293 13152 46633538
Haemoglobin increased 83.39 12.86 42 39330 2613 46644077
Renal impairment 82.40 12.86 189 39183 74183 46572507
Myelodysplastic syndrome 80.78 12.86 82 39290 15629 46631061
Renal failure 78.33 12.86 242 39130 113352 46533338
Condition aggravated 72.73 12.86 60 39312 244992 46401698
Mineral supplementation 69.65 12.86 24 39348 563 46646127
Peritonitis 67.02 12.86 85 39287 20629 46626061
Arthralgia 65.97 12.86 130 39242 364473 46282217
Drug intolerance 60.72 12.86 24 39348 147025 46499665
Rehabilitation therapy 59.59 12.86 26 39346 1166 46645524
Psoriasis 54.05 12.86 3 39369 78601 46568089
Joint swelling 53.94 12.86 37 39335 166036 46480654
Unevaluable event 52.96 12.86 119 39253 46056 46600634
Sinusitis 52.24 12.86 22 39350 129746 46516944
Hip fracture 52.16 12.86 86 39286 26470 46620220
Nephrogenic systemic fibrosis 51.36 12.86 38 39334 4734 46641956
Product use issue 51.24 12.86 9 39363 94635 46552055
Azotaemia 47.62 12.86 35 39337 4316 46642374
Refractory cytopenia with unilineage dysplasia 47.18 12.86 18 39354 569 46646121
Infusion related reaction 46.11 12.86 14 39358 101194 46545496
Pain 45.76 12.86 227 39145 476721 46169969
Weight increased 45.46 12.86 43 39329 164430 46482260
Drug interaction 45.42 12.86 63 39309 203031 46443659
Injection site erythema 45.16 12.86 5 39367 74422 46572268
Cardiac failure 44.94 12.86 159 39213 79789 46566901
Nausea 42.80 12.86 373 38999 687081 45959609
Cardiac output decreased 42.71 12.86 19 39353 893 46645797
Somnolence 42.01 12.86 42 39330 156479 46490211
Reticulocyte count decreased 41.65 12.86 15 39357 402 46646288
Anti-erythropoietin antibody negative 40.31 12.86 10 39362 68 46646622
Transformation to acute myeloid leukaemia 39.72 12.86 11 39361 120 46646570
Living in residential institution 38.88 12.86 14 39358 375 46646315
Arteriovenous fistula site infection 38.30 12.86 9 39363 47 46646643
Drug specific antibody absent 37.53 12.86 9 39363 52 46646638
Haemodialysis complication 35.98 12.86 12 39360 254 46646436
Depression 35.83 12.86 55 39317 170049 46476641
Hepatic cyst infection 35.32 12.86 10 39362 119 46646571
End stage renal disease 34.49 12.86 33 39339 5853 46640837
Dizziness 33.75 12.86 160 39212 340254 46306436
Alopecia 33.74 12.86 53 39319 162361 46484329
Reticulocyte count abnormal 32.56 12.86 8 39364 52 46646638
Blood parathyroid hormone increased 32.48 12.86 24 39348 2984 46643706
Renal cyst infection 32.43 12.86 9 39363 99 46646591
Off label use 31.98 12.86 473 38899 379368 46267322
Arthropathy 31.53 12.86 16 39356 84684 46562006
Disease progression 31.23 12.86 156 39216 91144 46555546
Treatment failure 31.20 12.86 20 39352 93067 46553623
Thrombocytopenia 31.18 12.86 198 39174 126383 46520307
Hepatic enzyme increased 31.13 12.86 15 39357 81772 46564918
Abdominal discomfort 30.76 12.86 50 39322 151115 46495575
Nasopharyngitis 30.35 12.86 52 39320 153946 46492744
Musculoskeletal stiffness 30.27 12.86 23 39349 97970 46548720
Therapeutic product effect incomplete 30.25 12.86 14 39358 78139 46568551
Cardiac disorder 29.78 12.86 93 39279 43765 46602925
Pleural effusion 29.27 12.86 143 39229 82809 46563881
Chronic kidney disease 28.99 12.86 88 39284 40783 46605907
Shunt infection 28.69 12.86 7 39365 44 46646646
Anti-erythropoietin antibody 28.05 12.86 5 39367 3 46646687
Product dose omission issue 27.14 12.86 64 39308 168456 46478234
Iron deficiency 26.51 12.86 28 39344 5585 46641105
Lower respiratory tract infection 26.31 12.86 104 39268 54985 46591705
Occupational exposure to product 26.29 12.86 17 39355 1704 46644986
Serum ferritin increased 26.11 12.86 27 39345 5256 46641434
Neoplasm malignant 25.20 12.86 59 39313 23440 46623250
Asthma 25.20 12.86 24 39348 91518 46555172
Migraine 24.93 12.86 14 39358 70012 46576678
Pain in extremity 24.79 12.86 123 39249 258557 46388133
Fungal endocarditis 24.69 12.86 9 39363 250 46646440
Peripheral swelling 24.69 12.86 61 39311 158010 46488680
Home care 24.32 12.86 4 39368 0 46646690
Leukopenia 24.23 12.86 118 39254 68225 46578465
Visual impairment 24.22 12.86 13 39359 66676 46580014
Memory impairment 24.08 12.86 18 39354 77319 46569371
Diabetic complication 23.69 12.86 13 39359 964 46645726
Swelling 23.66 12.86 43 39329 124468 46522222
Overdose 23.41 12.86 31 39341 101948 46544742
Injection site pruritus 23.29 12.86 3 39369 39740 46606950
Transplant failure 23.22 12.86 14 39358 1240 46645450
Injection site reaction 22.93 12.86 6 39366 47843 46598847
Eye infection bacterial 22.93 12.86 7 39365 110 46646580
Arthritis 22.80 12.86 19 39353 77297 46569393
Intentional product use issue 22.80 12.86 8 39364 52772 46593918
Pancytopenia 22.79 12.86 136 39236 84922 46561768
Fluid overload 22.63 12.86 62 39310 27123 46619567
Fall 22.48 12.86 396 38976 328701 46317989
Arteriovenous fistula thrombosis 22.37 12.86 8 39364 210 46646480
Anxiety 22.07 12.86 79 39293 181878 46464812
Skin induration 21.99 12.86 19 39353 2955 46643735
Hypertension 21.66 12.86 257 39115 196099 46450591
Insomnia 21.09 12.86 70 39302 164854 46481836
Systemic lupus erythematosus 20.51 12.86 15 39357 65165 46581525
Parakeratosis 20.40 12.86 7 39365 162 46646528
Product use in unapproved indication 20.15 12.86 28 39344 90245 46556445
Infective aneurysm 20.11 12.86 9 39363 429 46646261
Nephrogenic anaemia 20.06 12.86 15 39357 1898 46644792
Exposure during pregnancy 20.00 12.86 38 39334 108174 46538516
Agitation 19.84 12.86 11 39361 55404 46591286
Myelodysplastic syndrome transformation 19.67 12.86 9 39363 452 46646238
Nasal congestion 19.60 12.86 8 39364 48105 46598585
Marasmus 19.34 12.86 9 39363 470 46646220
Bone marrow failure 19.30 12.86 62 39310 29607 46617083
Blood cholesterol increased 19.21 12.86 5 39367 40008 46606682
Hyperphosphataemia 19.15 12.86 14 39358 1712 46644978
Urinary tract infection 19.15 12.86 276 39096 219990 46426700
Therapeutic product effect decreased 19.07 12.86 25 39347 82576 46564114
Blood erythropoietin increased 19.04 12.86 4 39368 11 46646679
Extramedullary haemopoiesis 18.92 12.86 5 39367 45 46646645
Sleep disorder 18.71 12.86 8 39364 46787 46599903
Kidney transplant rejection 18.49 12.86 20 39352 4098 46642592
Gait disturbance 18.33 12.86 62 39310 145201 46501489
Abortion spontaneous 18.20 12.86 7 39365 43639 46603051
Myalgia 18.06 12.86 49 39323 123039 46523651
Rash 18.05 12.86 203 39169 356309 46290381
Product quality issue 18.00 12.86 4 39368 35644 46611046
Blood creatinine increased 17.87 12.86 118 39254 76285 46570405
Product storage error 17.75 12.86 34 39338 11758 46634932
Sepsis 17.72 12.86 184 39188 135830 46510860
Blood test abnormal 17.58 12.86 30 39342 9490 46637200
Cough 17.48 12.86 118 39254 230131 46416559
Angina pectoris 17.46 12.86 56 39316 26719 46619971
Chronic kidney disease-mineral and bone disorder 17.21 12.86 7 39365 263 46646427
Hypersensitivity 17.09 12.86 67 39305 150254 46496436
Urine odour abnormal 17.06 12.86 21 39351 4941 46641749
Hypervolaemia 16.95 12.86 13 39359 1709 46644981
Pneumonia 16.93 12.86 426 38946 375894 46270796
Haemolysis 16.71 12.86 23 39349 6036 46640654
Blood product transfusion dependent 16.65 12.86 6 39366 161 46646529
Amegakaryocytic thrombocytopenia 16.55 12.86 4 39368 24 46646666
Natural killer cell count 16.55 12.86 4 39368 24 46646666
Wrong technique in product usage process 16.51 12.86 13 39359 54409 46592281
Dialysis related complication 16.41 12.86 5 39367 78 46646612
Renovascular hypertension 16.16 12.86 3 39369 3 46646687
Dry eye 16.15 12.86 3 39369 30319 46616371
Macrophages increased 16.15 12.86 4 39368 27 46646663
Cellulitis 16.10 12.86 108 39264 70180 46576510
Arteriovenous fistula occlusion 15.87 12.86 7 39365 322 46646368
Maternal condition affecting foetus 15.75 12.86 6 39366 189 46646501
Glossodynia 15.61 12.86 9 39363 44364 46602326
Hyperparathyroidism secondary 15.60 12.86 11 39361 1271 46645419
Skin hypertrophy 15.55 12.86 16 39356 3095 46643595
Blood potassium increased 15.44 12.86 40 39332 16927 46629763
Arteriovenous fistula site haemorrhage 15.31 12.86 6 39366 204 46646486
Osteoarthritis 15.12 12.86 18 39354 62007 46584683
Leg amputation 14.89 12.86 13 39359 2050 46644640
Epistaxis 14.84 12.86 99 39273 64206 46582484
Alanine aminotransferase increased 14.70 12.86 33 39339 88418 46558272
Shunt thrombosis 14.67 12.86 4 39368 41 46646649
Vascular shunt 14.63 12.86 3 39369 7 46646683
Medication error 14.58 12.86 4 39368 30907 46615783
Anaphylactic reaction 14.52 12.86 14 39358 53098 46593592
Plasma cell myeloma 14.49 12.86 75 39297 44403 46602287
Flushing 14.46 12.86 20 39352 64594 46582096
Intermittent claudication 14.21 12.86 12 39360 1808 46644882
Upper respiratory tract infection 13.90 12.86 20 39352 63536 46583154
Renal transplant failure 13.89 12.86 8 39364 651 46646039
Hepatitis 13.71 12.86 5 39367 32210 46614480
Skin ulcer 13.70 12.86 59 39313 32399 46614291
Skin fibrosis 13.62 12.86 9 39363 936 46645754
Loss of personal independence in daily activities 13.51 12.86 17 39355 57166 46589524
Pulmonary arterial hypertension 12.91 12.86 3 39369 25925 46620765

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 12374.60 13.69 6931 34658 350352 29560537
Hospitalisation 5084.15 13.69 2004 39585 42315 29868574
Aplasia pure red cell 1160.38 13.69 394 41195 5232 29905657
Haemodialysis 1016.46 13.69 429 41160 10644 29900245
Investigation 885.84 13.69 214 41375 697 29910192
Arteriovenous fistula site complication 716.53 13.69 157 41432 279 29910610
Transplant 443.17 13.69 115 41474 537 29910352
Dialysis 377.37 13.69 218 41371 10778 29900111
Peritoneal dialysis 264.35 13.69 73 41516 450 29910439
Haemoglobin abnormal 246.72 13.69 109 41480 3020 29907869
Haemoglobin decreased 227.59 13.69 494 41095 113604 29797285
Anti-erythropoietin antibody positive 193.65 13.69 65 41524 828 29910061
Therapeutic response decreased 184.34 13.69 197 41392 24152 29886737
Renal disorder 171.85 13.69 187 41402 23397 29887492
Terminal state 158.01 13.69 84 41505 3520 29907369
Anaemia 144.58 13.69 621 40968 207371 29703518
Transfusion 139.46 13.69 101 41488 7360 29903529
Palliative care 123.49 13.69 37 41552 316 29910573
Toxicity to various agents 118.42 13.69 49 41540 177134 29733755
Shunt stenosis 112.72 13.69 35 41554 341 29910548
Renal transplant 105.66 13.69 51 41538 1737 29909152
Arteriovenous fistula operation 101.37 13.69 27 41562 142 29910747
Reticulocyte count decreased 91.08 13.69 33 41556 534 29910355
Myelodysplastic syndrome 89.37 13.69 120 41469 18658 29892231
Haemoglobin increased 85.05 13.69 52 41537 2850 29908039
Drug interaction 80.80 13.69 95 41494 199473 29711416
Lower respiratory tract infection 74.04 13.69 133 41456 26581 29884308
Shunt occlusion 69.59 13.69 28 41561 610 29910279
Neoplasm malignant 68.74 13.69 103 41486 17711 29893178
Living in residential institution 68.43 13.69 21 41568 196 29910693
Hip fracture 65.43 13.69 79 41510 11045 29899844
Mineral supplementation 61.94 13.69 16 41573 73 29910816
Headache 59.61 13.69 101 41488 182205 29728684
Drug ineffective 57.79 13.69 260 41329 340127 29570762
Product use in unapproved indication 56.72 13.69 16 41573 73677 29837212
Transformation to acute myeloid leukaemia 55.79 13.69 24 41565 622 29910267
Nephrogenic systemic fibrosis 55.30 13.69 47 41542 4324 29906565
Azotaemia 52.17 13.69 48 41541 4904 29905985
Overdose 52.07 13.69 26 41563 84311 29826578
Chronic kidney disease 48.87 13.69 139 41450 37699 29873190
Arteriovenous fistula site infection 48.87 13.69 13 41576 68 29910821
Arteriovenous fistula thrombosis 48.01 13.69 18 41571 322 29910567
Peritonitis 46.43 13.69 96 41493 21279 29889610
Product use issue 46.20 13.69 5 41584 46011 29864878
Appendicolith 44.79 13.69 23 41566 896 29909993
Rehabilitation therapy 44.31 13.69 20 41569 583 29910306
Alanine aminotransferase increased 42.78 13.69 25 41564 74251 29836638
Unevaluable event 42.25 13.69 118 41471 31667 29879222
Product storage error 41.92 13.69 48 41541 6343 29904546
Angina pectoris 41.64 13.69 112 41477 29406 29881483
Somnolence 40.23 13.69 45 41544 96718 29814171
Aggression 39.76 13.69 3 41586 36904 29873985
Suicidal ideation 38.72 13.69 3 41586 36111 29874778
Refractory cytopenia with unilineage dysplasia 38.60 13.69 17 41572 467 29910422
Nausea 37.05 13.69 251 41338 296706 29614183
Zoonotic bacterial infection 36.58 13.69 10 41579 59 29910830
Depression 35.51 13.69 44 41545 90393 29820496
Hyperhidrosis 35.33 13.69 25 41564 67065 29843824
Intermittent claudication 34.53 13.69 27 41562 2207 29908682
Product dose omission issue 34.51 13.69 46 41543 91585 29819304
Hallucination 33.62 13.69 13 41576 49046 29861843
Rheumatoid arthritis 33.49 13.69 8 41581 41189 29869700
Home care 33.49 13.69 6 41583 0 29910889
Normochromic normocytic anaemia 33.38 13.69 34 41555 3936 29906953
Aspartate aminotransferase increased 32.91 13.69 24 41565 63398 29847491
Leg amputation 32.73 13.69 26 41563 2175 29908714
Fluid overload 32.72 13.69 78 41511 19014 29891875
Dizziness 32.29 13.69 150 41439 194759 29716130
Hepatic cyst infection 32.09 13.69 7 41582 12 29910877
Urinary tract infection 31.93 13.69 193 41396 73466 29837423
Arthralgia 30.64 13.69 92 41497 135699 29775190
Myalgia 30.41 13.69 37 41552 76630 29834259
Mycobacterium marinum infection 30.41 13.69 12 41577 248 29910641
Erythropoiesis abnormal 29.91 13.69 11 41578 186 29910703
Weight increased 29.88 13.69 36 41553 74877 29836012
Intentional product use issue 29.77 13.69 7 41582 36433 29874456
Angiodysplasia 29.46 13.69 14 41575 460 29910429
Tachycardia 28.81 13.69 36 41553 73703 29837186
Agitation 28.66 13.69 20 41569 54053 29856836
Interstitial lung disease 28.45 13.69 25 41564 60172 29850717
Drug hypersensitivity 28.32 13.69 32 41557 68487 29842402
Reticulocytopenia 28.22 13.69 8 41581 55 29910834
Joint swelling 28.18 13.69 15 41574 46931 29863958
Condition aggravated 27.92 13.69 98 41491 137768 29773121
Infusion related reaction 27.38 13.69 11 41578 40553 29870336
Tremor 26.23 13.69 40 41549 75323 29835566
Rhabdomyolysis 25.94 13.69 30 41559 63550 29847339
Treatment failure 25.81 13.69 8 41581 34671 29876218
Catheter removal 25.74 13.69 10 41579 198 29910691
Lactic acidosis 25.49 13.69 6 41583 31207 29879682
Cardio-respiratory arrest 24.52 13.69 26 41563 57280 29853609
Hepatic enzyme increased 24.44 13.69 8 41581 33486 29877403
Sinusitis 24.27 13.69 8 41581 33337 29877552
Transferrin saturation increased 23.88 13.69 7 41582 55 29910834
Blood iron abnormal 23.76 13.69 7 41582 56 29910833
End stage renal disease 23.17 13.69 39 41550 7396 29903493
Gangrene 22.73 13.69 30 41559 4584 29906305
Chest discomfort 22.58 13.69 18 41571 45462 29865427
Anti-erythropoietin antibody 22.32 13.69 4 41585 0 29910889
Blood creatine phosphokinase increased 22.22 13.69 17 41572 43831 29867058
Irritability 21.91 13.69 3 41586 23047 29887842
Anxiety 21.64 13.69 59 41530 89812 29821077
Pleural effusion 21.47 13.69 176 41413 73890 29836999
Catheter placement 21.27 13.69 13 41576 712 29910177
Non-neutralising antibodies positive 20.93 13.69 7 41582 88 29910801
Pyrexia 20.84 13.69 286 41303 294203 29616686
Angioedema 20.61 13.69 11 41578 34373 29876516
Renal cyst infection 19.95 13.69 6 41583 52 29910837
Insomnia 19.80 13.69 65 41524 93271 29817618
Hyperparathyroidism secondary 19.74 13.69 15 41574 1175 29909714
Drug-induced liver injury 19.69 13.69 3 41586 21271 29889618
Asthma 19.67 13.69 13 41576 36161 29874728
Respiratory failure 19.39 13.69 73 41516 100569 29810320
Parvovirus B19 test positive 19.28 13.69 7 41582 114 29910775
Renal transplant failure 19.12 13.69 14 41575 1037 29909852
Foetal exposure during pregnancy 19.06 13.69 14 41575 36857 29874032
Iron overload 18.76 13.69 15 41574 1266 29909623
Coronary artery disease 18.66 13.69 25 41564 49687 29861202
Skin induration 18.65 13.69 19 41570 2200 29908689
Skin fibrosis 18.63 13.69 14 41575 1079 29909810
Psoriasis 18.50 13.69 19 41570 42487 29868402
Cognitive disorder 18.48 13.69 5 41584 23685 29887204
Acute respiratory distress syndrome 18.23 13.69 5 41584 23467 29887422
Electrocardiogram QT prolonged 18.02 13.69 14 41575 35821 29875068
Arteriovenous fistula occlusion 17.77 13.69 7 41582 144 29910745
Blood product transfusion dependent 17.73 13.69 9 41580 342 29910547
Muscle spasms 17.61 13.69 40 41549 64798 29846091
Cardiac valve disease 17.43 13.69 21 41568 2928 29907961
Bradycardia 17.33 13.69 41 41548 65485 29845404
Reticulocyte count abnormal 17.33 13.69 4 41585 10 29910879
Acute kidney injury 17.26 13.69 272 41317 273570 29637319
Abnormal behaviour 17.21 13.69 7 41582 25616 29885273
Benign neoplasm 17.09 13.69 7 41582 160 29910729
Fall 16.89 13.69 350 41239 181522 29729367
Oedema due to renal disease 16.74 13.69 3 41586 0 29910889
Depressed level of consciousness 16.73 13.69 17 41572 38205 29872684
Toe amputation 16.71 13.69 18 41571 2223 29908666
Disturbance in attention 16.66 13.69 5 41584 22124 29888765
Abdominal pain upper 16.65 13.69 39 41550 62512 29848377
Heart valve operation 16.55 13.69 5 41584 44 29910845
Metastatic neoplasm 16.51 13.69 20 41569 2805 29908084
Blood bilirubin increased 16.38 13.69 16 41573 36620 29874269
Skin tightness 16.36 13.69 17 41572 2015 29908874
Rash 16.33 13.69 179 41410 191710 29719179
Oxygen saturation decreased 16.15 13.69 22 41567 43418 29867471
Sleep disorder 15.94 13.69 7 41582 24472 29886417
Inadequate osteointegration 15.91 13.69 4 41585 16 29910873
Pain in extremity 15.85 13.69 89 41500 110132 29800757
Memory impairment 15.75 13.69 17 41572 37157 29873732
Vision blurred 15.72 13.69 21 41568 41795 29869094
Delirium 15.69 13.69 20 41569 40611 29870278
Kidney infection 15.60 13.69 25 41564 4553 29906336
Serotonin syndrome 15.51 13.69 3 41586 17888 29893001
Fracture 15.49 13.69 29 41560 5977 29904912
Surgery 15.45 13.69 43 41546 11508 29899381
Weight decreased 15.26 13.69 135 41454 150786 29760103
Arteriovenous fistula site haemorrhage 15.25 13.69 6 41583 123 29910766
Visual impairment 15.17 13.69 12 41577 30426 29880463
Skin hypertrophy 14.93 13.69 18 41571 2511 29908378
Hyperphosphataemia 14.87 13.69 17 41572 2242 29908647
Hepatic function abnormal 14.84 13.69 22 41567 41923 29868966
Cardiac failure 14.79 13.69 179 41410 83239 29827650
Dysgeusia 14.77 13.69 8 41581 24793 29886096
Gallbladder disorder 14.72 13.69 28 41561 5839 29905050
Arteriovenous graft thrombosis 14.67 13.69 3 41586 3 29910886
Dyskinesia 14.60 13.69 6 41583 21828 29889061
Musculoskeletal stiffness 14.56 13.69 17 41572 35864 29875025
Depressed mood 14.46 13.69 3 41586 17026 29893863
Pneumonia 14.23 13.69 583 41006 333723 29577166
Dry mouth 14.16 13.69 7 41582 22843 29888046
Haematochezia 14.11 13.69 16 41573 34206 29876683
Dental restoration failure 14.05 13.69 4 41585 28 29910861
Dialysis device insertion 13.92 13.69 4 41585 29 29910860
Inappropriate schedule of product administration 13.90 13.69 21 41568 39707 29871182
Social problem 13.86 13.69 10 41579 724 29910165
Hepatotoxicity 13.84 13.69 4 41585 18141 29892748
Serum ferritin increased 13.71 13.69 26 41563 5411 29905478

Pharmacologic Action:

SourceCodeDescription
ATC B03XA02 BLOOD AND BLOOD FORMING ORGANS
ANTIANEMIC PREPARATIONS
OTHER ANTIANEMIC PREPARATIONS
Other antianemic preparations
FDA CS M0007726 Erythropoietin
FDA PE N0000009319 Increased Erythroid Cell Production
FDA EPC N0000175665 Erythropoiesis-stimulating Agent
MeSH PA D006397 Hematinics
MeSH PA D006401 Hematologic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Anemia of renal disease indication 234348004
Anemia due to and following chemotherapy indication 767657005
Hypertensive disorder contraindication 38341003 DOID:10763

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Erythropoietin receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
4021274 VANDF
C0937950 UMLSCUI
CHEMBL1201566 ChEMBL_ID
DB00012 DRUGBANK_ID
D000068256 MESH_DESCRIPTOR_UI
D03651 KEGG_DRUG
8073 INN_ID
15UQ94PT4P UNII
283838 RXNORM
16174 MMSL
235606 MMSL
42263 MMSL
d04771 MMSL
009195 NDDF
385608005 SNOMEDCT_US
385610007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-002 SOLUTION 25 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-003 SOLUTION 40 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-004 SOLUTION 60 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-005 SOLUTION 100 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-006 SOLUTION 200 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-021 INJECTION, SOLUTION 40 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-023 INJECTION, SOLUTION 60 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-025 INJECTION, SOLUTION 100 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-027 INJECTION, SOLUTION 150 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-028 INJECTION, SOLUTION 200 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-032 INJECTION, SOLUTION 500 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-057 INJECTION, SOLUTION 25 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-098 INJECTION, SOLUTION 10 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-110 SOLUTION 300 ug INTRAVENOUS BLA 29 sections
ARANESP HUMAN PRESCRIPTION DRUG LABEL 1 55513-111 INJECTION, SOLUTION 300 ug INTRAVENOUS BLA 29 sections